Kunshi Biotechnology Raises Angel Funding for Engineered Macrophage Platform
China-based Kunshi Biotechnology (Shenzhen) Co., Ltd, a company specializing in gene editing, biomaterials, and synthetic...
Company
Akeso Biopharma’s Cadonilimab Recommended as First-Line Treatment for Cervical Cancer
China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included...
Fosun Kite’s Yescarta Gains Priority Review Status for r/r LBCL
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group)...
Genor Biopharma Initiates First Patient Dosing for GB263T in China
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced the first patient dosing in a...
Akeso Biopharma Gains NMPA Approval for AK112 and AK119 Clinical Study
China-based Akeso Biopharma (HKG: 9926) has announced receiving approval from the National Medical Products Administration...
Innovent Biologics Publishes Mazdutide Phase Ib Study Results for Obesity
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the results of the higher-dose cohorts...
Sihuan Pharma to Acquire Additional Stake in Heilongjiang Duoduo Pharma
China-based Sihuan Pharmaceutical Holdings Group Ltd’s subsidiary, Beijing Centergate Technologies (Holding) Co., Ltd (SHE: 000931),...
BeiGene’s Brukinsa Receives Positive CHMP Opinion for CLL Approval
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving a positive opinion...
Kira Pharmaceuticals Gains NMPA Approval for Phase II Study of KP104 in PNH
Sino-US biotech Kira Pharmaceuticals has announced receiving approval from the National Medical Products Administration (NMPA)...
RemeGen’s Telitacicept Gains EU, China Approvals for Global Phase III Study
China-based pharma firm RemeGen (HKG: 9995) has announced receiving approvals from authorities in the European...
Zelgen’s Jacktinib Shows Strong Efficacy in Phase III Myelofibrosis Study
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has published major data from a Phase III...
Ningbo Menovo to Sell Zhejiang Liaoyuan Pharma Stake to Jemincare for RMB 512.58M
China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to transfer all of...
Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development
Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV)...
Alioth Biotech Raises RMB 100M in Series A Financing for Pharma Processing Products
China-based Alioth Biotech (Shanghai) Co., Ltd has raised close to RMB 100 million (USD 13.9...
HICOMP MicroTech Raises RMB 100M in Series B+ Financing for Microfluidics Expansion
China-based micro/nano technology developer HICOMP MicroTech (Suzhou) Co., Ltd has raised RMB 100 million (USD...
Kintor’s Dual c-Myc/GSPT1 Degradation Therapy GT19715 Shows Promise in Pre-Clinical Studies
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published positive results from a pre-clinical study of...
CARsgen’s BCMA-Targeted CAR-T Therapy CT053 Gains Priority Review in China
The Center for Drug Evaluation (CDE) website indicates that China-based chimeric antigen receptor (CAR)-T cell...
LianBio Cancels Phase III Trial for Truseltiq in China Amid Global Halt
China-based LianBio (OTCMKTS: LIANY) revealed in an SEC filing that it is canceling work on...
Accutar Biotechnology Initiates Phase I Trial for ERα Targeting Degradation Molecule AC0682
New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the...
RemeGen’s Telitacicept Receives FDA Orphan Drug Designation for Myasthenia Gravis
China-based pharma firm RemeGen (HKG: 9995, SHA: 688331) has announced receiving Orphan Drug Designation (ODD)...